Triple-negative breast cancer is a particularly challenging form of the disease because it lacks the three common targets used in traditional treatments. Unlike other breast cancers, it does not have estrogen receptors, progesterone receptors, or HER2 proteins, which are typically used to guide therapies. This absence means that hormone-based treatments and drugs targeting HER2 are ineffective, leaving fewer options for treatment. Dr. Olivier Marpeau, a gynecologist and researcher known on Instagram as @mon.gyneco, has been working alongside scientists at the Curie Institute to explore why some tumors resist treatment and how research is progressing to better understand and manage this aggressive cancer. In a recent video, Dr. Marpeau discussed these challenges with researcher Fatima Mechta-Grigoriou, highlighting the need for new approaches to tackle this difficult-to-treat condition. The video explains that the lack of these three receptors makes triple-negative breast cancer more complex to treat. Without these targets, doctors cannot use the standard therapies that work for other breast cancer types, such as hormone therapy or drugs that target HER2. As a result, treatment often relies on chemotherapy or newer targeted therapies that are still being developed. Dr. Marpeau emphasized that understanding the mechanisms behind resistance is a key area of research, as it could lead to more effective treatments in the future. According to the National Cancer Institute, triple-negative breast cancer tends to grow more quickly and is more likely to recur compared to other types of breast cancer. This aggressive nature makes early detection and treatment even more critical. Researchers are now looking into alternative strategies, such as immunotherapy and precision medicine, to find better ways to treat patients who do not respond to traditional therapies. These efforts are part of a broader push to personalize cancer treatment based on the unique characteristics of each patient's tumor. The collaboration between Dr. Marpeau and the Curie Institute highlights the importance of public engagement in scientific research. By using social media platforms like Instagram, researchers can share their findings with a wider audience and help raise awareness about the challenges of triple-negative breast cancer. This kind of outreach not only educates the public but also encourages participation in clinical trials and other research efforts that could lead to breakthroughs in cancer treatment.